One World Protected

The Gavi COVAX AMC Investment Opportunity Launch Event

15 April 2021 | 14:00 CET



View programme

Video stories

Gavi COVAX AMC – Investment Opportunity

Last updated on 15 April 2021

View full screen

DOWNLOAD: English | French | SpanishChinese | Arabic | Italian


On 15 April, Gavi and the United States government brought together world leaders, the private sector, civil society and key technical partners to galvanise resources and commitment to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC).

The One World Protected event launched the Investment Opportunity for the Gavi COVAX AMC, outlining the urgent need for its continued support and paving the way for a funding Summit in June.

Learn more



José Manuel Barroso
Chair of the Gavi Board



Antony Blinken
Secretary of State, United States



Gloria Steele
USAID Acting Administrator

Key figures

Population >143 million pandemic-induced global new poor in 2021.
Economy US$ 9 trillion potential loss to the global economy if COVID-19 vaccines aren’t globally distributed.
Doses 1.8 billion doses of COVID-19 vaccine could be reserved through the Gavi COVAX AMC in 2021.
Economies 92 lower-income economies stand to benefit from COVID-19 vaccines provided through the Gavi COVAX AMC.
Funding ≥ US$ 2 billion is required by June 2021 to fully fund the Gavi COVAX AMC.

The Gavi COVAX Advance Market Commitment (AMC) is an innovative financial mechanism that ensures the world’s poorest countries will get access to COVID-19 vaccines, regardless of their ability to pay.

United States support for Gavi

In addition to committing US$ 4 billion over 2021 and 2022 to support Gavi’s COVID-19 related work, the U.S. is a long-standing supporter of Gavi. It was one of the Alliance’s original six donors and has contributed more than US$ 2.7 billion to our core work since 2000.

U.S. global health assistance has emphasised ending preventable child deaths through high-impact, low-cost interventions, and provision of vaccines and immunisations through Gavi is an important component of these efforts. Moreover, the United States continues to be a key partner to Gavi by coordinating programmatic objectives to ensure greater efficiency and impact on the ground.

Timeline of U.S. support for Gavi

  • 2000: One of the original six founding donors of Gavi
  • 2011: Pledges US$ 450 million at Gavi’s first replenishment 
  • 2015: Pledges US$ 1 billion to Gavi for 2015-2018 period
  • 2017: Announces US$ 20 million to support Gavi’s Ebola vaccine stockpile
  • 2020: Pledges US$ 1.16 billion to Gavi for the period 2020-2023
  • 2020: Provides US$ 4 billion for COVID-19 vaccine procurement and delivery, becoming Gavi’s largest donor
  • 2021: Hosts the One World Protected launch meeting (virtual event)

Gavi COVAX AMC donors

COVAX AMC donors table

Latest COVAX AMC news

26 July 2021

“I will definitely take the vaccine”: High demand for COVID-19 vaccines in Uganda

While there was some initial reluctance to get vaccinated against COVID-19 in Eastern Uganda, attitudes are changing fast.

21 July 2021

From town criers to local monarchs: encouraging COVID-19 vaccination in Southern Nigeria

Volunteers, including King Dakolo of the Epetiama kingdom, are sensitising and convincing people to accept the COVID-19 vaccine in Bayelsa State, Southern Nigeria.

21 July 2021

Nurses on the COVID-19 frontlines in Sierra Leone

#VaccinesWork spoke to nurse Fatmata Kamara* about how the COVID-19 vaccine roll-out in Sierra Leone is progressing.

20 July 2021

The COVAX No Fault Compensation Programme: Explained

Indemnity and liability was one of the thorniest problems COVAX had to solve to successfully roll out COVID-19 vaccines in lower-income countries. The solution is a world first, which could offer a model for future pandemics.

5 July 2021

Kenyans use their polio fighting network to tackle COVID-19

A rich network of community volunteers in Nairobi are putting skills they developed during anti-polio activities to work tackling COVID-19, and mobilising slum dwellers to get the COVID-19 vaccine.

Last updated: 2 Jun 2021

Subscribe to our newsletter